N-Acetylcysteine Amide Therapy for Retinitis Pigmentosa Oxidative Stress

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for retinitis pigmentosa (RP) do not stop the progression of the disease or restore vision, and existing therapies like N-acetyl-L-cysteine (NAC) are limited by low membrane penetration and low systemic bioavailability.

Innovation Solution

Administering N-acetylcysteine amide (NACA) via various routes, including intraocular, subretinal, and oral, to increase glutathione levels and protect cellular compartments from oxidative stress, using a therapeutically effective amount and potentially combined with other active agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If N-acetyl-L-cysteine (NAC) is administered to treat retinitis pigmentosa, then oxidative stress is reduced and cone cell death is decreased, but membrane penetration is low and systemic bioavailability is poor

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidmembrane penetration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent modifies the chemical structure of NAC by replacing the carboxylic acid group with an amide group to create NACA. This parameter change in molecular structure fundamentally alters the compound's properties, enabling it to penetrate the blood-retina barrier effectively while maintaining the critical thiol antioxidant functionality that provides therapeutic benefit against oxidative stress in retinitis pigmentosa.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite therapeutic approach by combining NACA with other antioxidants such as vitamin E, vitamin C, and lipoic acid. This composite formulation synergistically enhances the overall therapeutic effectiveness against oxidative stress while each component contributes its unique properties, overcoming the limitations of single-agent therapy.

Inventive Principle:

Principle #40Composite materials

2Reliability

If N-acetyl-L-cysteine (NAC) is administered to treat retinitis pigmentosa, then oxidative stress is reduced and cone cell death is decreased, but systemic bioavailability is low

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidsystemic bioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If current therapies are used to slow down degenerative process, then progression is slightly delayed, but vision restoration is not achieved and disease modification does not occur

Engineering Contradiction:

Improvedisease progression delayVSAvoidvision restoration

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent employs preliminary protective action by administering NACA before significant cone cell death occurs. The compound prevents oxidative damage proactively, preserving cone function and structure in early and intermediate stages of retinitis pigmentosa. This preliminary protection can delay disease progression and potentially preserve vision before irreversible damage occurs, creating a window for effective intervention.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention converts the harmful oxidative stress that drives retinitis pigmentosa progression into a beneficial therapeutic target. By using NACA to specifically counteract oxidative damage through its thiol antioxidant mechanism, the treatment transforms the disease's primary pathological mechanism into its point of vulnerability, where targeted antioxidant therapy can effectively slow or halt progression.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

NACA effectively reduces cone cell death and preserves cone function, slowing the degenerative process and potentially preventing the onset of blindness in RP, offering a novel treatment approach.

Implementation Method 1

oxidative stress in the outer retina is severe and leads to gradual cone cell death

Methodology Applied

Scientific EffectOxidative stress: Oxidation

Implementation Method 2

NACA is able to treat RP in vivo... NACA effectively reduces cone cell death and preserves cone function

Methodology Applied

Scientific EffectAntioxidant activity: Reduction

Data Source

PatentUS12472157B2Treatment of retinitis pigmentosa with n-acetylcysteine amide

Publication Date: 2025.11.18 NACUITY PHARMACEUTICALS INC

AI summary

The present invention includes a method for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA). In accordance with an embodiment, the present invention provides a method for the treatment of retinitis pigmentosa in an animal that comprises administering to the animal a therapeutically effective amount of N-acetylcystein amide (NACA).